Ceftolozane-Tazobactam

ApprovedSmall molecule

TTemple University

Ceftolozane-Tazobactam is one of 47 small molecule programs targeting Neutropenia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeutropeniaActive, not recruiting

Pseudomonas InfectionActive, not recruiting

Gram-Negative Bacterial InfectionsActive, not recruiting

NeutropeniaApproved

Active, not recruiting

Pseudomonas InfectionPreclinical

Active, not recruiting

Gram-Negative Bacterial InfectionsApproved

Active, not recruiting

Competition

Competitive Landscape

124 competitors in Neutropenia

#DrugCompanyPhaseTrials

Cubicin

BBaxter Healthcare Corporation

Phase 3

3 2

Mycostatin

GGood Molecules, LLC

Phase 3

1 3

Caspofungin Acetate

Merck & Co.

Phase 3

4 4

Amphotericin B Deoxycholate

Merck & Co.

Phase 3

1 5

Liposomal Lurtotecan

Gilead

Phase 3

1 6

Alcohol

Astellas

Phase 3

—7

Ceftolozane-Tazobactam

TTemple University

Approved

1 8

G-CSF

AArog Pharmaceuticals, Inc.

Phase 3

3 9

Jardiance

Boehringer Ingelheim

Phase 2

3 10

Kineret

SSwedish Orphan Biovitrum

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Neutropenia

NCT06342115

Q4 2028

Post-ApprovalRecruiting

Gram-Negative Bacterial Infections

NCT07004049

Clinical

Trials by Indication[1]

Neutropenia1 trial

Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens

Recruiting·BBeneficência Portuguesa de São Paulo·Phase 4·NCT06342115·176 enrolled

Pseudomonas infection1 trial

Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections

Unknown status·TTemple University··NCT03510351·200 enrolled

Bloodstream Infection1 trial

Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection

Withdrawn·TThe University of Queensland·Phase 3·NCT04238390

Gram-Negative Bacterial Infections1 trial

Optimising TREATment for Severe Gram-Negative Bacterial Infections

Recruiting·NNational University of Singapore·Phase 4·NCT07004049·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Ceftolozane-Tazobactam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ceftolozane-Tazobactam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ceftolozane-Tazobactam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Temple University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TTemple University

Ceftolozane-Tazobactam

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Trials by Indication[1]

Neutropenia1 trial

Pseudomonas infection1 trial

Bloodstream Infection1 trial

Gram-Negative Bacterial Infections1 trial

References

Drug Info

Quick Facts

Related News